OLD Mission Capital LLC acquired a new stake in shares of Mylan (NASDAQ:MYL) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 5,070 shares of the company’s stock, valued at approximately $215,000.
Other large investors also recently added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in shares of Mylan by 7.2% during the 3rd quarter. Rhumbline Advisers now owns 791,463 shares of the company’s stock valued at $24,828,000 after purchasing an additional 53,154 shares during the period. Hexavest Inc. raised its stake in shares of Mylan by 1.7% during the 4th quarter. Hexavest Inc. now owns 1,435,251 shares of the company’s stock valued at $60,725,000 after purchasing an additional 23,353 shares during the period. AMP Capital Investors Ltd raised its stake in shares of Mylan by 82.0% during the 3rd quarter. AMP Capital Investors Ltd now owns 642,574 shares of the company’s stock valued at $20,158,000 after purchasing an additional 289,485 shares during the period. Synovus Financial Corp raised its stake in shares of Mylan by 7.1% during the 4th quarter. Synovus Financial Corp now owns 30,921 shares of the company’s stock valued at $1,309,000 after purchasing an additional 2,045 shares during the period. Finally, Engineers Gate Manager LP raised its stake in shares of Mylan by 90.0% during the 3rd quarter. Engineers Gate Manager LP now owns 57,136 shares of the company’s stock valued at $1,792,000 after purchasing an additional 27,071 shares during the period. Institutional investors own 84.51% of the company’s stock.
Several equities analysts recently commented on the company. Cantor Fitzgerald set a $34.00 target price on Mylan and gave the stock a “hold” rating in a research report on Thursday, November 30th. ValuEngine upgraded Mylan from a “hold” rating to a “buy” rating in a research report on Friday, December 1st. UBS set a $46.00 target price on Mylan and gave the stock a “buy” rating in a research report on Monday, December 4th. Guggenheim assumed coverage on Mylan in a research report on Tuesday, December 12th. They set a “buy” rating and a $59.00 target price for the company. Finally, BidaskClub upgraded Mylan from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 19th. Nine analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $46.62.
Shares of Mylan stock opened at $41.73 on Monday. The firm has a market capitalization of $21,481.84, a PE ratio of 9.15, a P/E/G ratio of 1.32 and a beta of 1.35. Mylan has a fifty-two week low of $29.39 and a fifty-two week high of $47.82. The company has a current ratio of 1.13, a quick ratio of 0.73 and a debt-to-equity ratio of 1.06.
Mylan (NASDAQ:MYL) last issued its earnings results on Wednesday, February 28th. The company reported $1.43 earnings per share for the quarter, beating the consensus estimate of $1.41 by $0.02. The company had revenue of $3.24 billion during the quarter, compared to analysts’ expectations of $3.29 billion. Mylan had a return on equity of 19.14% and a net margin of 5.84%. Mylan’s quarterly revenue was down .9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.57 EPS. equities analysts predict that Mylan will post 5.38 earnings per share for the current fiscal year.
In related news, Director Robert J. Coury sold 150,000 shares of the stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $40.10, for a total transaction of $6,015,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Heather M. Bresch sold 75,000 shares of the stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total value of $3,375,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 344,287 shares of company stock valued at $14,409,960 over the last 90 days. 0.69% of the stock is currently owned by company insiders.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.